Bortezomib in Multiple Myeloma and Lymphoma

A clinical practice guideline for adult patients with multiple myeloma or lymphoma. The guideline examines the efficacy of bortezomib as a single-agent or combination therapy. Outcomes of interest include improved time to progression and improved outcomes for relapsing patients.